| Literature DB >> 28398598 |
P H O'Donnell1,2,3, N Wadhwa4, K Danahey2,5, B A Borden2, S M Lee6, J P Hall2, C Klammer2, S Hussain2, M Siegler1,2,3,7, M J Sorrentino1,2, A M Davis1,2, Y A Sacro1,2, R Nanda1,2, T S Polonsky1,2, J L Koyner1,2, D L Burnet1,2, K Lipstreuer1,2, D T Rubin1,2, C Mulcahy1,2, M E Strek1,2,3, W Harper1,2, A S Cifu1,2, B Polite1,2, L Patrick-Miller8, K-Tj Yeo9, Eky Leung9, S L Volchenboum5, R B Altman10, O I Olopade1, W M Stadler1,2, D O Meltzer1,11, M J Ratain1,2,3.
Abstract
Changes in behavior are necessary to apply genomic discoveries to practice. We prospectively studied medication changes made by providers representing eight different medicine specialty clinics whose patients had submitted to preemptive pharmacogenomic genotyping. An institutional clinical decision support (CDS) system provided pharmacogenomic results using traffic light alerts: green = genomically favorable, yellow = genomic caution, red = high risk. The influence of pharmacogenomic alerts on prescribing behaviors was the primary endpoint. In all, 2,279 outpatient encounters were analyzed. Independent of other potential prescribing mediators, medications with high pharmacogenomic risk were changed significantly more often than prescription drugs lacking pharmacogenomic information (odds ratio (OR) = 26.2 (9.0-75.3), P < 0.0001). Medications with cautionary pharmacogenomic information were also changed more frequently (OR = 2.4 (1.7-3.5), P < 0.0001). No pharmacogenomically high-risk medications were prescribed during the entire study when physicians consulted the CDS tool. Pharmacogenomic information improved prescribing in patterns aimed at reducing patient risk, demonstrating that enhanced prescription decision-making is achievable through clinical integration of genomic medicine.Entities:
Mesh：
Year: 2017 PMID： 28398598 PMCID： PMC5636653 DOI： 10.1002/cpt.709
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875